Abstract:The Nobel Prize in Chemistry 2012 was awarded jointly to Robert J.Lefkowitz and Brian K.Kobilka "for studies of G-protein-coupled receptors".Robert J.Lefkowitz discovered β-arrestin1 more than 20 years ago,when he studied the mechanism of β-AR(β-adrenergic receptor) desensitization,and proved that it involves in the desensitization,internalization and degradation of β-AR in his subsequent researches.More recently,new evidence has revealed the "biased agonism" of β-arrestin dependent signal pathway of β-AR,which is independent of G protein.Excitingly,this biased signaling was suggested to confer cardioprotection.In addition,β-AR blockers were discovered and widely used in the pharmacotherapy of cardiovascular diseases among many other β-AR targeted cardiovascular drugs,which was a breakthrough in the 20th century.However,most of these drugs take effect only by regulating the β-AR itself and block all of the signal pathways and functions,including both the pathological signaling and effect induced by the increased stimulation of β-AR and the normal physiological ones,which leads to some severe adverse reactions.Therefore,it will be a great progress in the treatment of cardiovascular diseases to develop the drug that can both selectively block the harmful signaling and effect and activate the beneficial physiological signaling(such as the β-arrestin signaling) of β-AR.The research and development of ligand drug for β-AR will focus on its highly selective downstream signal pathways.This article is to review the discovery of the β-arrestin and its interaction with β-AR,to offer a reference for the pharmacotherapy of cardiovascular diseases.

β-arrestin and β-adrenergic Receptor